OverviewSuggest Edit

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. The Company leverages the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. Aptevo’s ADAPTIR technology is suitable for producing immunotherapeutics for oncology, hematology, and autoimmune and inflammatory diseases.

TypePublic
Founded2016
HQSeattle, US
Websiteaptevotherapeutics.com

Latest Updates

Employees (est.) (Dec 2018)118(-2%)
Revenue (FY, 2018)$23.1 M(+58%)
Share Price (Oct 2019)$0.6 (+13%)

Key People/Management at Aptevo Therapeutics

Marvin L. White

Marvin L. White

President and Chief Executive Officer
Jeff Lamothe

Jeff Lamothe

SVP and Chief Financial Officer
Scott C. Stromatt

Scott C. Stromatt

M.D., Chief Medical Officer & SVP, Clinical Development & Medical Affairs
Randy J. Maddux

Randy J. Maddux

SVP and Chief Manufacturing Officer
Jane Gross

Jane Gross

Ph.D., SVP and Chief Scientific Officer
Mike Adelman

Mike Adelman

SVP, Commercial Operations
Show more

Aptevo Therapeutics Office Locations

Aptevo Therapeutics has an office in Seattle
Seattle, US (HQ)
2401 4th Ave #1050
Show all (1)

Aptevo Therapeutics Financials and Metrics

Aptevo Therapeutics Revenue

Embed Graph
View revenue for all periods
Aptevo Therapeutics's revenue was reported to be $23.07 m in FY, 2018 which is a 57.4% increase from the previous period.
USD

Net income (Q2, 2019)

(13.3m)

EBIT (Q2, 2019)

(12.9m)

Market capitalization (16-Oct-2019)

28.6m

Closing stock price (16-Oct-2019)

0.6

Cash (30-Jun-2019)

21.0m

EV

27.2m
Aptevo Therapeutics's current market capitalization is $28.6 m.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

36.4m14.7m23.1m

Revenue growth, %

(60%)57%

Cost of goods sold

24.2m5.0m11.2m

Gross profit

12.3m9.6m11.9m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

10.2m9.4m4.1m6.8m5.8m

Cost of goods sold

6.5m6.2m1.8m2.5m2.4m3.8m6.0m

Gross profit

3.6m3.2m2.3m4.3m3.4m

Gross profit Margin, %

36%34%56%63%58%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

9.7m7.1m30.6m

Accounts Receivable

4.3m2.1m5.2m

Inventories

6.6m1.0m1.8m

Current Assets

71.4m95.1m48.7m
Quarterly
USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

5.5m10.9m14.0m22.3m75.8m11.8m7.2m28.4m37.0m21.0m

Accounts Receivable

8.5m3.0m1.9m4.7m528.0k3.1m6.1m6.2m5.8m7.4m

Inventories

20.1m11.6m8.1m8.0m1.2m1.3m3.0m4.0m4.3m7.0m

Current Assets

39.8m79.4m77.4m67.2m115.3m77.2m66.2m60.4m57.6m43.7m
Annual
USDFY, 2017FY, 2018

Net Income

7.0m(53.7m)

Depreciation and Amortization

3.1m2.4m

Inventories

(567.0k)(757.0k)

Cash From Operating Activities

(41.6m)(51.4m)
Quarterly
USDQ2, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(25.7m)(9.9m)(21.1m)16.7m(13.9m)(27.0m)(39.6m)(12.0m)(25.3m)

Depreciation and Amortization

1.7m990.0k2.2m3.0m587.0k1.2m1.8m583.0k1.2m

Inventories

192.0k(1.4m)(1.3m)(776.0k)(257.0k)(1.9m)(2.9m)(2.6m)(5.2m)

Accounts Payable

387.0k
USDY, 2019

EV/EBIT

-2.1 x

EV/CFO

-0.9 x

Financial Leverage

2.5 x
Show all financial metrics

Aptevo Therapeutics Online and Social Media Presence

Embed Graph

Aptevo Therapeutics News and Updates

Aptevo Therapeutics Reports Second Quarter 2019 Financial Results

Reports Positive Preliminary Top-Line Safety Data for APVO210Phase 1 Single Ascending Dose (SAD) Clinical Study

Aptevo Therapeutics Reports Continued Progress In APVO210 and APVO436 Clinical Trials

Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210

Aptevo Therapeutics Reports First Quarter 2019 Financial Results

Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue

Polycystic Kidney Disease Treatment Market to witness huge growth by 2025 | Angion Biomedica, Aptevo Therapeutics, Celgene

HTF MI recently introduced Global Polycystic Kidney Disease Treatment Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday

Aptevo Therapeutics Reports Third Quarter 2018 Financial Results

Achieves 132% Increase in IXINITY® Quarterly Net Revenue Year-Over-Year

Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting

LUND, Sweden and SEATTLE, Nov. 9, 2018 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, and Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on...
Show more

Aptevo Therapeutics Blogs

Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited

Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited Content Import Wed, 08/07/2019 - 09:02 Aptevo Therapeutics Receives $4.3 Million Milestone Payment From Saol International Limited 08/07/19 This release is a backfill f…

Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients

Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients Content Import Tue, 06/25/2019 - 09:01 Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenien…

Aptevo Therapeutics Reports IXINITY® and Pipeline Progress

Aptevo Therapeutics Reports IXINITY® and Pipeline Progress Content Import Mon, 04/15/2019 - 09:04 Aptevo Therapeutics Reports IXINITY® and Pipeline Progress 04/15/19 This release is a backfill from a News Wire General Reports 73% Incr…

Aptevo Therapeutics Presents New Preclinical Data for APVO436 and ALG.APV-527 at the American Association for Cancer Research 2019 Annual Meeting

APVO436 Preclinical Data Continue to Show Promising Results Supporting Clinical Development for the Treatment of Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS) and Differentiation from a Competitor Candidate Phase 1/1b Clinical Study of APVO436 Continuing Dose

Aptevo Therapeutics to Present New Preclinical Data for APVO436 and ALG.APV.527 at the American Association for Cancer Research 2019 Annual Meeting

SEATTLE , March 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, today announced that preclinical data for two of its ADAPTIR™ bispecific antibody candidates will be presented

Aptevo Therapeutics Begins Phase 1 Clinical Trial of APVO210 a Novel Bispecific Antibody for the Treatment of Autoimmune and Inflammatory Diseases

Unique Mechanism of Action Suppresses Inflammation and Immune Activation  Without Promoting Pro-Inflammatory Lymphocyte Stimulation Preliminary Phase 1 Data Read-outs Anticipated Q3 and Q4 2019 SEATTLE , March 20, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc.
Show more

Aptevo Therapeutics Frequently Asked Questions

  • When was Aptevo Therapeutics founded?

    Aptevo Therapeutics was founded in 2016.

  • Who are Aptevo Therapeutics key executives?

    Aptevo Therapeutics's key executives are Marvin L. White, Jeff Lamothe and Scott C. Stromatt.

  • How many employees does Aptevo Therapeutics have?

    Aptevo Therapeutics has 118 employees.

  • What is Aptevo Therapeutics revenue?

    Latest Aptevo Therapeutics annual revenue is $23.1 m.

  • What is Aptevo Therapeutics revenue per employee?

    Latest Aptevo Therapeutics revenue per employee is $195.5 k.

  • Who are Aptevo Therapeutics competitors?

    Competitors of Aptevo Therapeutics include XBiotech, Aeglea Biotherapeutics and Heat Biologics.

  • Where is Aptevo Therapeutics headquarters?

    Aptevo Therapeutics headquarters is located at 2401 4th Ave #1050, Seattle.

  • Where are Aptevo Therapeutics offices?

    Aptevo Therapeutics has an office in Seattle.

  • How many offices does Aptevo Therapeutics have?

    Aptevo Therapeutics has 1 office.